Neoleukin Therapeutics, Inc. announced the appointment of Priti Patel, M.D., M.S., as Chief Medical Officer. Dr. Patel joins the company from AstraZeneca, where she served as Vice President, Head of Hematology Clinical Development since 2019. Previously, she served as Senior Medical Director and Executive Medical Director at Acerta Pharma before its acquisition by AstraZeneca. During her time at AstraZeneca and Acerta, Dr. Patel led clinical development strategy and trial execution of investigational therapeutics for blood cancers. This included leading over 6 Phase 3 studies and 20 Phase 1/2 studies for acalabrutinib as monotherapy and combination therapy for solid tumors and hematological cancers with global approvals in chronic lymphocytic leukemia and mantle cell lymphoma. Prior to that, Dr. Patel served as Medical Director at Onyx Pharmaceuticals where she helped guide strategic clinical development efforts in the development and approval of carfilzomib, an FDA-approved therapy for the treatment of multiple myeloma.